AFRICA HIGHLY AFFECTED
The rates of resistant forms of tuberculosis treatment have never been higher, revealed the World Health Organization (WHO), in a report released Tuesday, February 26. The international agency estimated that half a million the number of resistant forms on an annual total of 9 million TB cases.
The countries of the former Soviet Union and China registering the largest rate. Surveys in the Eastern countries have also shown a proportion of tuberculosis multidrug twice as high when the patient is also infected with the AIDS virus. In addition, 45 countries have reported at least one case of ultra-resistant tuberculosis, a form of the disease almost impossible to treat.
This report is the fourth since 1997 for this contagious and infectious disease that affects mostly the lungs. It is based on data on more than 90000 patients, collected between 2002 and 2006 in 82 countries.
For that TB is seen as multidrug (MR), its agent, the Koch bacillus, should not be susceptible to the two most effective anti-TB drugs, isoniazid and rifampicin. In cases - even tougher - of drug-resistant tuberculosis (UR), in addition to isoniazid and rifampicin, or molecules of the family of fluoroquinolones or injectable antibiotics are active.
Baku, the capital of Azerbaijan, holds the record proportion of tuberculosis multidrug: 22.3% of TB cases identified. This proportion reached 19.4% in Moldova and 16% in the Donetsk region (Ukraine).
The magnitude of the phenomenon is still not identified in Africa, a region where the incidence of tuberculosis is highest. Only six countries have been able to transmit data on the phenomenon of resistance. Among them, Rwanda presents the highest proportion of TB MR, with 3.9%.
The forms ultrarésistantes represent a quarter of multiresistant tuberculosis in Estonia. Each year occur approximately 40000 cases of tuberculosis UR in the world.
WHO estimates that more than 3 billion euros to effectively combat tuberculosis in countries with low-or intermediate, of which at least 20% on the forms and UR MR. It said the funding gap currently reach 1.6 billion euros, of which 330 million for the forms and MR UR
The countries of the former Soviet Union and China registering the largest rate. Surveys in the Eastern countries have also shown a proportion of tuberculosis multidrug twice as high when the patient is also infected with the AIDS virus. In addition, 45 countries have reported at least one case of ultra-resistant tuberculosis, a form of the disease almost impossible to treat.
This report is the fourth since 1997 for this contagious and infectious disease that affects mostly the lungs. It is based on data on more than 90000 patients, collected between 2002 and 2006 in 82 countries.
For that TB is seen as multidrug (MR), its agent, the Koch bacillus, should not be susceptible to the two most effective anti-TB drugs, isoniazid and rifampicin. In cases - even tougher - of drug-resistant tuberculosis (UR), in addition to isoniazid and rifampicin, or molecules of the family of fluoroquinolones or injectable antibiotics are active.
Baku, the capital of Azerbaijan, holds the record proportion of tuberculosis multidrug: 22.3% of TB cases identified. This proportion reached 19.4% in Moldova and 16% in the Donetsk region (Ukraine).
The magnitude of the phenomenon is still not identified in Africa, a region where the incidence of tuberculosis is highest. Only six countries have been able to transmit data on the phenomenon of resistance. Among them, Rwanda presents the highest proportion of TB MR, with 3.9%.
The forms ultrarésistantes represent a quarter of multiresistant tuberculosis in Estonia. Each year occur approximately 40000 cases of tuberculosis UR in the world.
WHO estimates that more than 3 billion euros to effectively combat tuberculosis in countries with low-or intermediate, of which at least 20% on the forms and UR MR. It said the funding gap currently reach 1.6 billion euros, of which 330 million for the forms and MR UR
posted by news of france at
10:48 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home